Replies to post #28376 on NanoViricides Inc. (NNVC)

[BonelessCat]

Those 40 million shares simply establish a reserve. It's my opinion that the company really only needs about $10 million to get past Phase 1 clinical studies for one drug. If we think in terms of which indication is easiest and quickest to assess, we can get an idea for what the docs have in mind. Me, I'm partial to FluCide. A clinical study can be started and completed in less than a month and evaluated and reported to the FDA within 6 months.